PEEL-224 + Vincristine + Temozolomide for Sarcoma

Recruiting at 2 trial locations

Overseen By David Shulman, MD

Age: < 65

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: David S Shulman, MD

Must not be taking: CYP1A2/3A4 inhibitors/inducers

Disqualifiers: Pregnancy, Breastfeeding, Organ transplant, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: Up to 2 years

63 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new drug combination for certain types of sarcomas, including Ewing Sarcoma and Desmoplastic Small Round Cell Tumor. Researchers aim to evaluate the effectiveness of PEEL-224, an experimental treatment, when combined with Vincristine and Temozolomide. The trial targets individuals whose sarcoma has returned or resisted standard treatments. Suitable candidates include those with a sarcoma diagnosis who have not responded to other treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

Will I have to stop taking my current medications?

The trial does not specify if you must stop taking your current medications, but you cannot be on other anti-cancer agents or certain strong enzyme inhibitors or inducers. It's best to discuss your current medications with the trial team to see if they are allowed.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Previous studies have not yet led to FDA approval of PEEL-224 for treating sarcomas, so researchers continue to study its safety. This drug aims to target tumors more effectively and reduce chemotherapy resistance. Since this research remains in the early stages, detailed safety information is limited.

Temozolomide, another drug in the trial, has FDA approval for certain types of brain cancer. It can cause side effects like low blood cell counts and nausea, but these are usually manageable.

Vincristine, also part of the trial, is approved for use in various cancers. It can sometimes cause side effects like nerve problems and hair loss, but its safety is well understood due to its widespread use.

Overall, this clinical trial is in the early stages, meaning researchers are still learning about the best dose and possible side effects. Participants will be closely monitored to ensure their safety. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about PEEL-224 combined with Temozolomide and Vincristine for treating sarcoma because this regimen might offer a new approach to managing the disease. Unlike traditional chemotherapy, which broadly targets rapidly dividing cells, PEEL-224 is believed to work by specifically targeting cancer cells, potentially increasing effectiveness while reducing side effects. Additionally, the combination of these drugs aims to enhance the overall cancer-fighting power, possibly leading to better outcomes for patients with difficult-to-treat sarcomas. This innovative approach could represent a significant step forward compared to existing treatments.

What evidence suggests that this trial's treatments could be effective for sarcomas?

Research has shown that PEEL-224, a new drug under study in this trial, could effectively treat sarcomas, a type of cancer. In early studies with mice, PEEL-224 outperformed irinotecan for conditions like Ewing Sarcoma and Desmoplastic Small Round Cell Tumor. Participants in this trial will receive PEEL-224 combined with Vincristine and Temozolomide. Vincristine is part of successful chemotherapy plans that improve survival rates in Ewing Sarcoma. Temozolomide has shown some success, especially when combined with other drugs, in treating recurrent sarcomas. This drug combination aims to leverage the strengths of each to enhance treatment outcomes. ^{1 6 7 8 9}

Who Is on the Research Team?

David S Shulman, MD

Principal Investigator

Dana-Farber Cancer Institute

Are You a Good Fit for This Trial?

This trial is for adolescents and young adults with certain types of sarcomas that have come back or didn't respond to previous treatments. Participants should be diagnosed with conditions like Ewing Sarcoma or Desmoplastic Small Round Cell Tumor, among others.

Inclusion Criteria

I am between 12 and 49 years old.

My blood, kidney, liver, and heart are functioning well.

I have recovered from side effects of my previous cancer treatment.

Exclusion Criteria

Breastfeeding mothers

Pregnant participants

My cancer progressed despite treatment with irinotecan and temozolomide.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Treatment

Participants receive PEEL-224 in combination with Vincristine and Temozolomide in 21-day cycles, with imaging every 2 cycles until Cycle 6 and then every 3 cycles

Up to 2 years

In-clinic visits for each cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment

1 year

What Are the Treatments Tested in This Trial?

Interventions

• PEEL-224
• Temozolomide
• Vincristine

Trial Overview

The study tests a new drug, PEEL-224, combined with Vincristine and Temozolomide. It aims to find out how effective this mix is against various sarcomas in those who've had relapses or refractory disease.

How Is the Trial Designed?

Group I: Phase 2: Dose Expansion Other Sarcoma Experimental Treatment 5 Interventions

Administration of PEEL-224 will be at the RP2D, and safety monitoring rules will be applied for the occurrence of dose-limiting toxicities. 15 participants will be enrolled and will complete: * Baseline visit with assessments and imaging * Cycle 1 (21 day cycle): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily * Cycle 2 through End of Treatment (21 day cycles): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Imaging every 2 cycles until Cycle 6 and then every 3 cycles * End of study visit

Group II: Phase 2: Dose Expansion Ewing Sarcoma Experimental Treatment 5 Interventions

Administration of PEEL-224 will be at the RP2D, and safety monitoring rules will be applied for the occurrence of dose-limiting toxicities. 15 participants will be enrolled and will complete: * Baseline visit with assessments and imaging * Cycle 1 (21 day cycle): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily * Cycle 2 through End of Treatment (21 day cycles): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Imaging every 2 cycles until Cycle 6 and then every 3 cycles * End of study visit

Group III: Phase 2: Dose Expansion DSRCT Experimental Treatment 5 Interventions

Administration of PEEL-224 will be at the RP2D, and safety monitoring rules will be applied for the occurrence of dose-limiting toxicities. 15 participants will be enrolled and will complete: * Baseline visit with assessments and imaging * Cycle 1 (21 day cycle): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily * Cycle 2 through End of Treatment (21 day cycles): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Imaging every 2 cycles until Cycle 6 and then every 3 cycles * End of study visit

Group IV: Phase 1: Dose Escalation PEEL-224 Dose Level 2 Experimental Treatment 5 Interventions

Establishment of the MTD/RP2D will be determined by the CRM design. * Baseline visit with assessments and imaging * Cycle 1 (21 day cycle): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily * Cycle 2 through End of Treatment (21 day cycles): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Imaging every 2 cycles until Cycle 6 and then every 3 cycles * End of study visit

Group V: Phase 1: Dose Escalation PEEL-224 Dose Level 1 Experimental Treatment 5 Interventions

Escalation to Dose Level 2 or establishment of the MTD/RP2D will be determined by the CRM design. * Baseline visit with assessments and imaging * Cycle 1 (21 day cycle): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily * Cycle 2 through End of Treatment (21 day cycles): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Imaging every 2 cycles until Cycle 6 and then every 3 cycles * End of study visit

Group VI: Phase 1: Dose Escalation PEEL-224 Dose Level 0 Experimental Treatment 5 Interventions

Up to 15 participants will be enrolled using a Bayesian design, the Continual Reassessment Method (CRM), to determine the maximum tolerated dose of PEEL-224 and starting at Dose Level 0. Transition to a lower dose level will be determined by types of dose-limiting toxicities observed per the protocol. * Baseline visit with assessments and imaging * Cycle 1 (21 day cycle): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily * Cycle 2 through End of Treatment (21 day cycles): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Imaging every 2 cycles until Cycle 6 and then every 3 cycles * End of study visit

Group VII: Phase 1: Dose Escalation PEEL-224 Dose Level -2 Experimental Treatment 5 Interventions

Establishment of the MTD/RP2D will be according to the CRM design. * Baseline visit with assessments and imaging * Cycle 1 (21 day cycle): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily * Cycle 2 through End of Treatment (21 day cycles): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Imaging every 2 cycles until Cycle 6 and then every 3 cycles * End of study visit

Group VIII: Phase 1: Dose Escalation PEEL-224 Dose Level -1B Experimental Treatment 5 Interventions

Transition to a lower dose level will be determined by types of dose-limiting toxicities observed per the protocol, otherwise establishment of the MTD/RP2D will be according to the CRM model. * Baseline visit with assessments and imaging * Cycle 1 (21 day cycle): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily * Cycle 2 through End of Treatment (21 day cycles): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Imaging every 2 cycles until Cycle 6 and then every 3 cycles * End of study visit

Group IX: Phase 1: Dose Escalation PEEL-224 Dose Level -1A Experimental Treatment 5 Interventions

Transition to a lower dose level will be determined by types of dose-limiting toxicities observed per the protocol, otherwise establishment of the MTD/RP2D will be according to the CRM model. * Baseline visit with assessments and imaging * Cycle 1 (21 day cycle): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Day 10: Myeloid growth factor (Pegfilgrastim or Filgrastim) administration 1x daily * Cycle 2 through End of Treatment (21 day cycles): * Days 1 through 5: Predetermined dose of Temozolomide 1x daily * Days 1 and 8: Predetermined dose of PEEL-224 1x daily and predetermined dose of Vincristine 1x daily * Imaging every 2 cycles until Cycle 6 and then every 3 cycles * End of study visit

Who Is Running the Clinical Trial?

David S Shulman, MD

Lead Sponsor

Trials

1

Recruited

60+

Peel Therapeutics Inc

Industry Sponsor

Trials

3

Recruited

160+

Published Research Related to This Trial

A combination of temozolomide and irinotecan was found to be tolerable and active in treating advanced Ewing sarcoma, with 1 complete response and 3 partial responses observed among 14 evaluable patients.

The treatment regimen was manageable, with minimal myelosuppression and only 11% of courses experiencing grade 3-4 diarrhea, suggesting that home administration of irinotecan is safe and feasible for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Wagner, LM., McAllister, N., Goldsby, RE., et al.[2018]

The VIT regimen, consisting of vincristine, irinotecan, and temozolomide, showed an overall control rate of 52% in treating relapsed or refractory sarcomas in a study of 26 patients, indicating its potential efficacy for this challenging condition.

The treatment was relatively safe, with no reported treatment-related mortality, and demonstrated promising survival rates of 79.3% at 1 year and 45.5% at 2 years, suggesting it could be a viable option for young patients with limited treatment options.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults. Ju, HY., Park, M., Lee, JA., et al.[2022]

In a phase I trial involving 38 patients with advanced solid tumors, the combination of intravenous methoxyamine (MX) and oral temozolomide (TMZ) was found to be safe, with no dose-limiting toxicities observed, allowing for a maximum tolerated dose of TMZ at 200 mg/m² daily for 5 days alongside MX at 150 mg/m² on day 1.

The trial showed that while there were some grade 3 and 4 adverse events, the combination therapy resulted in a partial response in one patient and prolonged stable disease in six others, suggesting potential efficacy in certain tumor types.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors. Eads, JR., Krishnamurthi, SS., Saltzman, J., et al.[2022]

Temozolomide (TMZ) is well tolerated in patients with glioma and melanoma, with dose-limiting toxicity primarily being thrombocytopenia, observed at maximum tolerated doses of 150 mg/m2/day for patients with prior nitrosourea exposure and 250 mg/m2/day for those without.

The study showed promising antitumor activity, with two complete responses in patients without prior nitrosourea treatment, suggesting that TMZ could be an effective treatment option for these patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Dhodapkar, M., Rubin, J., Reid, JM., et al.[2018]

In a phase II trial involving 38 patients with recurrent oligodendroglial tumors, temozolomide (TMZ) demonstrated a high response rate, with 52.6% of patients showing a complete or partial response, indicating its efficacy as a first-line chemotherapy.

TMZ was generally well tolerated, with hematologic side effects being the most common, and only one patient discontinuing treatment due to toxicity, suggesting a favorable safety profile for chemotherapy-naive patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. van den Bent, MJ., Taphoorn, MJ., Brandes, AA., et al.[2022]

In a phase II trial involving 26 patients with advanced mycosis fungoides/Sézary syndrome, temozolomide (TMZ) showed an overall response rate of 27%, with 8% achieving complete remission and 19% partial remission, indicating its potential efficacy in this patient population.

Despite the low levels of MGMT in malignant CD4(+) T cells, which suggested sensitivity to TMZ, the study found that pretreatment levels of MGMT and mismatch repair proteins did not predict treatment response, indicating that other resistance mechanisms may be at play.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins. Querfeld, C., Rosen, ST., Guitart, J., et al.[2021]

The protracted d × 5×2 schedule of vincristine, irinotecan, and temozolomide (VIT) demonstrated a significantly higher objective response rate (54.5%) compared to the shorter d × 5 schedule (20.8%) in patients with relapsed or refractory Ewing sarcoma, based on a study of 46 patients.

Patients on the d × 5 schedule experienced more severe adverse events, indicating that the d × 5×2 schedule not only provided better efficacy but also had a more favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial. Xu, J., Xie, L., Sun, X., et al.[2023]

The TMZ-resistant glioma cell line SF188/TR showed a 6-fold resistance to temozolomide and cross-resistance to various other anticancer agents, indicating a significant challenge in treating resistant tumors.

Increased activity of the enzyme alkylguanine alkyltransferase (AGT) was identified as a primary mechanism of resistance to TMZ, while changes in the balance of pro-apoptotic and anti-apoptotic proteins contributed to broader cross-resistance to other drugs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Ma, J., Murphy, M., O'Dwyer, PJ., et al.[2022]

In a phase II trial involving 46 patients with progressive low-grade glioma, Temozolomide (Temodar) demonstrated a 61% objective response rate, with 24% achieving complete response and 37% achieving partial response.

The treatment showed promising safety, with limited toxicity observed; however, one patient experienced severe complications, highlighting the need for careful monitoring during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase II trial of temozolomide in patients with progressive low-grade glioma. Quinn, JA., Reardon, DA., Friedman, AH., et al.[2022]

Temozolomide is a promising drug for combination therapies due to its ability to cross the blood-brain barrier, good safety profile, and effectiveness against solid tumors like malignant glioma, especially when combined with carmustine or irinotecan.

Studies indicate that administering carmustine before temozolomide results in lower toxicity and a higher maximum tolerated dose, while the combination of temozolomide followed by irinotecan shows greater effectiveness than either drug alone.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Temozolomide in combination with other cytotoxic agents. Prados, M.[2019]

Ecteinascidin-743 (ET-743) demonstrated activity in advanced soft tissue sarcoma and osteosarcoma patients, with two partial responses and ten disease stabilizations observed among 29 patients treated in a phase I study and compassionate use program.

The treatment was generally well-tolerated, though some patients experienced significant side effects, including grade 3 to 4 neutropenia in 32% of treatment cycles, indicating that while ET-743 can be effective, monitoring for adverse effects is important.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. Delaloge, S., Yovine, A., Taamma, A., et al.[2018]

In a study involving 46 children with solid tumors resistant to conventional therapy, NSC-45388 was administered safely at doses of 200-450 mg/m2/day for 5 consecutive days, with major toxic effects including nausea and decreased blood cell counts.

Objective responses to NSC-45388 were observed in 3 children with neuroblastoma and 1 child with rhabdomyosarcoma, indicating that while the drug has minimal activity as a single agent, it shows potential for further evaluation in combination therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of solid tumors in children. Finklestein, JZ., Albo, V., Ertel, I., et al.[2016]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06709495

Study Details | NCT06709495 | Phase 1/2 Trial to Evaluate ...

This research is being done to test a new drug called PEEL-224 in combination with two commercially available drugs, Vincristine and Temozolomide.

2.

dana-farber.org

dana-farber.org/clinical-trials/24-591

Phase 1/2 trial to evaluate the safety and efficacy of PEEL- ...

Phase 1/2 trial to evaluate the safety and efficacy of PEEL-224 in combination with vincristine and temozolomide in adolescents and young adults

3.

research.chop.edu

research.chop.edu/cornerstone-blog/chop-developed-drug-for-high-risk-tumors-advances-to-clinical-trials-in-children

CHOP-developed Drug for High-risk Tumors Advances to ...

PEEL-224, a therapy to treat high-risk tumors, enters a pediatric clinical trial after a decade of groundbreaking research.

4.

researchgate.net

researchgate.net/publication/396808476_Abstract_B001_Phase_12_trial_to_evaluate_the_safety_and_efficacy_of_PEEL-224_in_combination_with_vincristine_and_temozolomide_in_adolescents_and_young_adults_with_relapsed_or_refractory_sarcomas

Abstract B001: Phase 1/2 trial to evaluate the safety and ...

Pre-clinical data in EWS, DSRCT and RMS mouse models demonstrate significantly improved efficacy over irinotecan. METHODS This prospective, open ...

5.

ascopubs.org

ascopubs.org/doi/10.1200/PO-25-00377

Recurrent and Refractory Ewing Sarcoma Phase I/II Trials

Mean DCR was 44.1% and RR was 7.7%. However, disease was not controlled in a large proportion of patients (89/207) and the median PFS was 9.15 ...

6.

trials.braintumor.org

trials.braintumor.org/trials/NCT06709495

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL ...

The U.S. Food and Drug Administration (FDA) has not approved PEEL-224 as a treatment for Relapsed or Refractory Sarcoma. The U.S. Food and Drug ...

7.

peeltx.com

peeltx.com/news/peel-therapeutics-closes-new-financing-round-and-expands-board-of-directors-to-support-evolution-based-medicines-for-cancer-and-inflammation/

Peel Therapeutics to Present Data on its TOP1 Inhibitor ...

PEEL-224 is a small molecule nanoparticle engineered to improve delivery to tumors and avoid chemoresistance.

8.

clinicaltrials.gov

clinicaltrials.gov/study/NCT05329103

NCT05329103 | A Study to Evaluate PEEL-224 in Patients ...

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity ...

9.

cancer.gov

cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-00630

PEEL-224, Vincristine and Temozolomide for the ...

This phase I/II trial tests the safety, side effects, best dose and how well PEEL-224, vincristine and temozolomide works in treating adolescents and young ...